Home > Healthcare > Medical Devices > Diagnostic Devices > Europe Laboratory Developed Tests Market

Europe Laboratory Developed Tests Market Share

Report ID: GMI9341
Published Date: May 2024
Report Format: PDF

Download Free Sample

Europe Laboratory Developed Tests Market Share

Collaboration is key for key players to expand their reach, access new markets, and drive innovation. They form strategic partnerships and collaborations with healthcare institutions, research organizations, diagnostic manufacturers, and technology providers to leverage complementary expertise, resources, and capabilities. Partnerships facilitate the development, validation, and commercialization of new LDTs and foster collaboration across the healthcare ecosystem.

Europe Laboratory Developed Tests Market Companies

Some of the eminent market participants operating in the Europe laboratory developed tests industry include:

23andMe, Inc.
Abbott
Bio-Rad Laboratories, Inc.
Eurofins Scientific
F. Hoffmann-La Roche Ltd.
Illumina, Inc.
OPKO Health, Inc.
QIAGEN
Quest Diagnostics Incorporated
SVAR Lifesciences

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Europe laboratory developed tests market size was valued at USD 2.1 billion in 2023 and is estimated to grow at 6.1% CAGR from 2024 to 2032 owing to rising demand for infectious disease testing, increasing healthcare expenditure.

The oncology segment in the Europe laboratory developed tests market held over 28% share in 2023, driven by the differentiation between benign and malignant lesions, and guide treatment decisions based on tumor histology and molecular characteristics.

Germany laboratory developed tests market size reached USD 362.7 million in revenue in 2023, attributed to leading academic institutions, research organizations, and biotechnology companies.

23andMe, Inc., Abbott, Bio-Rad Laboratories, Inc., Eurofins Scientific, F. Hoffmann-La Roche Ltd., Illumina, Inc., OPKO Health, Inc., QIAGEN, Quest Diagnostics Incorporated and SVAR Lifesciences